Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

amaxa to Co-ordinate Collaboration to Develop High Throughput Devices for Primary Cell Transfection

Published: Monday, July 02, 2007
Last Updated: Monday, July 02, 2007
Bookmark and Share
amaxa receives a €2.75M grant from European Commission to develop devices for use in the study of immunological, neuronal and liver disorders.

amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders.

The collaboration has been granted over €2.75 million in funding from the EC and will use amaxa’s Nucleofector® Technology – a method for the transfection of primary cells.

The 36-month project, named MODEST-EU, is a collaboration between amaxa AG (Germany), Deutsches Rheumaforschungszentrum (Germany), RNAx GmbH (Germany), Protobios Ltd (Estonia), Fotec Forschungs- und Technologietransfer GmbH (Austria), HTP High Tech Plastics AG (Austria), Dominion Pharmakine SL (Spain) and Prevas AB (Sweden).

The devices developed using amaxa’s Nucleofector® Technology will represent the world’s first technology enabling high-throughput screenings in transfected and differentiated primary cells. The project will go on to study the application of this technology in the areas of immunology, neurology and liver disorders.

Dr. Birgit Nelsen-Salz, coordinator of the project, said “amaxa is the only institution worldwide, which has the necessary knowledge and experience to adapt the technical needs of device development to the conditions used for efficient transfection of primary cells and hard-to-transfect cell lines. As co-ordinator of the project we will ensure that the expertise brought by each partner will enable the collaboration to achieve the goal of providing powerful new tools for basic research and drug discovery”.

Each partner will play a significant role in the development of the devices: Prevas will be responsible for the building of the device from proof-of-principle up to prototype; Fotec will develop the production process for micro-plates; HTP will be involved in the prototyping of the 384-well plates.

In addition, the application of nucleofection and cell based assays will be assessed by a team of outstanding experts: DRFZ (cell sorting and multiparameter flow-cytometry), RNAx (RNAi technology), Protobios (nervous system development and transcription regulation network) and Dominion Pharmakine (biomarkers related to site specific development of liver metastasis).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!